Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SKYE | CLUSTER | bearish | 4/10 | Two 10% owners of Skye Bioscience sold a combined $125K in open-market sales at $1.91/share within a 7-day window. The t | Sep 18, 2026 |
| RVMD | CLUSTER | bearish | 5/10 | Three insiders at Revolution Medicines sold a total of $5.37M in stock over a one-week window, led by a $4.33M sale by a | Sep 18, 2026 |
| LABT | S-1 | bearish | 5/10 | Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an S-1 registration statement to register an additional 4,512,400 shar | Sep 18, 2026 |
| BSEM | S-1 | bearish | 7/10 | BioStem Technologies filed an S-1 registration statement to register up to 12,050,000 shares of common stock for resale | Sep 18, 2026 |
| ADIL | DEFA14A | neutral | 5/10 | Adial Pharmaceuticals filed this DEFA14A to report results from its 2026 Annual Meeting held September 17, 2026. Stockho | Sep 18, 2026 |
| QCLS | 8-K | neutral | 3/10 | Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer, promoted from Founding Manager of PIC Developm | Sep 18, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity issued a $2,126,250 senior secured convertible note to J.J. Astor & Co., receiving net proceeds of $1,501,850 | Sep 18, 2026 |
| NEUP | DEFA14A | neutral | 3/10 | Neuphoria Therapeutics Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, in | Sep 18, 2026 |
| INM | 8-K | bearish | 6/10 | InMed Pharmaceuticals received a Nasdaq deficiency notice for failing to meet the minimum $2.5M shareholders' equity req | Sep 18, 2026 |
| MBRX | 8-K | bearish | 8/10 | Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating that its common stock clos | Sep 18, 2026 |
| CNEY | 6-K | bearish | 7/10 | CN Energy Group reported a net loss of $49.5 million for the six months ended March 31, 2026, compared to net income of | Sep 18, 2026 |
| QNRX | S-3 | bearish | 6/10 | Quoin Pharmaceuticals filed an S-3 registration statement to register 9,371,895 ADSs for resale by selling shareholders | Sep 18, 2026 |
| ATOS | 8-K | neutral | 3/10 | Atossa Therapeutics filed an 8-K on September 18, 2026, to make available an updated corporate investor presentation (Ex | Sep 18, 2026 |
| ALEC | SC 13G | neutral | 4/10 | Biotechnology Value Fund L.P. (BVF), a dedicated healthcare hedge fund, filed a new Schedule 13G disclosing a 7.7% benef | Sep 18, 2026 |
| ETRA | 424B4 | bullish | 7/10 | Electra Therapeutics priced its IPO of 23,333,334 shares at $15.00 per share, raising $350.0 million in gross proceeds ( | Sep 18, 2026 |
| KRSA | 144 | neutral | 2/10 | Director Errol B. De Souza filed a Form 144 notice of intent to sell 2,139 shares of Korsana Biosciences common stock, w | Sep 18, 2026 |
| ETRA | 3 | neutral | 3/10 | OrbiMed Advisors and its affiliates filed a Form 3 initial statement of beneficial ownership for Electra Therapeutics, I | Sep 18, 2026 |
| NSRX | 424B5 | bearish | 5/10 | Nasus Pharma filed a prospectus supplement for an at-the-market (ATM) offering of up to $8.5 million of ordinary shares | Sep 18, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | CEO Martine Rothblatt sold ~$7.5M in open-market shares over three days (Sep 14-16), following a $477.6M accelerated sha | Sep 18, 2026 |
| NEUP | DEFA14A | neutral | 3/10 | Neuphoria Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, alongsi | Sep 18, 2026 |
| NEUP | DEF 14A | neutral | 3/10 | Neuphoria Therapeutics Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held | Sep 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new real-world data at Psych Congress showing that UZEDY (risperidone) extended-release injectable suspen | Sep 18, 2026 |
| OTLK | 8-K | neutral | 3/10 | Outlook Therapeutics announced the U.S. wholesale acquisition cost (WAC) for LYTENAVA at $485 per vial on September 16, | Sep 18, 2026 |
| BYSI | 8-K | bearish | 7/10 | BeyondSpring received a Nasdaq deficiency notice on September 17, 2026, for failing to maintain a minimum $1.00 closing | Sep 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented new post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting in | Sep 18, 2026 |
| ADIL | 8-K | neutral | 4/10 | Adial Pharmaceuticals held its 2026 Annual Meeting on September 17, 2026, where stockholders approved the 2026 Equity In | Sep 18, 2026 |
| ETRA | 3 | neutral | 2/10 | Matthew Fust filed a Form 3 initial statement of beneficial ownership with Electra Therapeutics, Inc., disclosing stock | Sep 18, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders at Arcutis Biotherapeutics sold a combined $206K in open-market sales over a one-week window. Director Howa | Sep 18, 2026 |
| ETRA | 3 | neutral | 2/10 | Carl L. Gordon, a director and OrbiMed affiliate, filed a Form 3 initial statement of beneficial ownership with Electra | Sep 18, 2026 |
| FLNA | 8-K | bearish | 7/10 | Filana Therapeutics received a Nasdaq deficiency notice on September 17, 2026, because its common stock bid price closed | Sep 18, 2026 |